This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Arnold L. Potosky, PhD, MHS; Barry A. Miller, MSPH; Peter C. Albertsen, MD; Barnett S. Kramer, MD, MPH

JAMA. 1995;273(7):548-552.

Abstract
Objective.
—To assess the reasons for the dramatic surge in prostate cancer incidence from 1986 to 1991.

Design.
—Population-based study of incidence rates and procedures used to detect and diagnose prostate cancer derived from Medicare claims data and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program from 1986 to 1991.

Setting.
—Four SEER areas (Connecticut; Atlanta, Ga; Detroit, Mich; and Seattle—Puget Sound, Wash) covering approximately 6% of the US population.

Participants.
—A 5% random sample of male fee-for-service Medicare beneficiaries aged 65 years and older without cancer, and all men with prostate cancer diagnosed at 65 years of age and older residing in the four areas.

Main Outcome Measures.
—The age-adjusted rates of prostate cancer incidence, prostate needle biopsy, transurethral resection of the prostate, serum prostate-specific antigen (PSA) testing, and transrectal ultrasound.

Results.
—The age-adjusted incidence rate of prostate cancer among men aged 65 years and older in the four SEER areas rose 82% from 1986 to 1991, with the largest annual increases occurring in 1990 (20%) and 1991 (19%). Prostate needle biopsy rates increased while the use of transurethral resection of the prostate declined from 1986 to 1991. The rising needle biopsy rate has been driven by an exponential increase in PSA testing in the general population from 1988 to 1991 and, to a much lesser extent, the increasing use of transrectal ultrasound since 1986. The use of PSA or transrectal ultrasound has increased across age and race groups and in different geographic areas. However, there remain wide geographic variations in the use of PSA screening.

Conclusions.
—The recent dramatic epidemic of prostate cancer is likely the result of the increasing detection of tumors resulting from increased PSA screening. The magnitude and rapidity of the incidence rise suggest that changes in the intensity of medical surveillance is the most plausible explanation for this trend.

Implications.
—The rapid diffusion of screening interventions that have the ability to detect latent asymptomatic disease leads to important concerns regarding costs and patient quality of life for men aged 65 years and older. Geographic variability in the adoption of PSA testing underscores uncertainty and disagreement about its value for reducing prostate cancer mortality. More research is required to determine the effectiveness of screening for prostate cancer.

(JAMA. 1995;273:548-552)

Author Affiliations
From the Applied Research Branch (Dr Potosky) and the Cancer Statistics Branch (Mr Miller), Surveillance Program, and the Early Detection and Community Oncology Program (Dr Kramer), Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, Md, and the Division of Urology, University of Connecticut Health Center, Farmington (Dr Albertsen).

Footnotes
Reprint requests to Applied Research Branch, National Cancer Institute, 6130 Executive Blvd, EPN Room 313, Bethesda, MD 20892-7344 (Dr Potosky).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole et al.
NEJM 2009;360:1310-1319.
ABSTRACT | FULL TEXT  

Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention
Lucia et al.
Cancer Prevention Research 2008;1:167-173.
ABSTRACT | FULL TEXT  

A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
Sedjo et al.
CA Cancer J Clin 2007;57:326-340.
ABSTRACT | FULL TEXT  

Diagnostic Performance of a Random Versus Lesion-Directed Biopsy of the Prostate From Transrectal Ultrasound: Results of a 5-Year Consecutive Clinical Study in 1 Institution in South Taiwan
Lan et al.
J Ultrasound Med 2007;26:11-17.
ABSTRACT | FULL TEXT  

Randomized Clinical Trials for Cancer Screening: Rationale and Design Considerations for Imaging Tests
Black
JCO 2006;24:3252-3260.
ABSTRACT | FULL TEXT  

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran
Safarinejad
Ann Oncol 2006;17:1166-1171.
ABSTRACT | FULL TEXT  

The Effectiveness of Screening for Prostate Cancer: A Nested Case-Control Study
Concato et al.
Arch Intern Med 2006;166:38-43.
ABSTRACT | FULL TEXT  

Metabolic Syndrome and the Risk of Prostate Cancer in Finnish Men: A Population-Based Study
Laukkanen et al.
Cancer Epidemiol. Biomarkers Prev. 2004;13:1646-1650.
ABSTRACT | FULL TEXT  

Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer
Kelloff et al.
Clin. Cancer Res. 2004;10:3927-3933.
FULL TEXT  

Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer
Nam et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1429-1437.
ABSTRACT | FULL TEXT  

Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control
Weir et al.
JNCI J Natl Cancer Inst 2003;95:1276-1299.
ABSTRACT | FULL TEXT  

The Prostate Cancer Conundrum
Albertsen
JNCI J Natl Cancer Inst 2003;95:930-931.
FULL TEXT  

Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection
Nam et al.
JCO 2003;21:2312-2319.
ABSTRACT | FULL TEXT  

Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut
Lu-Yao et al.
BMJ 2002;325:740-740.
ABSTRACT | FULL TEXT  

Measurement of Prostate-specific Antigen by Use of a Novel Blood Collection and Analytical System
Grzeda et al.
Clin. Chem. 2002;48:1272-1278.
ABSTRACT | FULL TEXT  

State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer
Goodin et al.
The Oncologist 2002;7:360-370.
ABSTRACT | FULL TEXT  

Language and Medicine: Thinking and Talking About Alzheimer's Disease
Goodwin
Gerontologist 2002;42:293-296.
FULL TEXT  

Androgen Deprivation as Primary Treatment for Early Prostate Cancer: Should We "Just Do Something"?
Talcott
JNCI J Natl Cancer Inst 2002;94:407-409.
FULL TEXT  

PSA screening and prostate cancer mortality
Perron et al.
CMAJ 2002;166:586-591.
ABSTRACT | FULL TEXT  

Hospitalization for Prostate Cancer Among the Older Men in the Longitudinal Study on Aging, 1984-1991
Wolinsky et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57:M115-121.
ABSTRACT | FULL TEXT  

Prevalence-corrected Prostate Cancer Incidence Rates and Trends
Merrill and Morris
Am J Epidemiol 2002;155:148-152.
ABSTRACT | FULL TEXT  

High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers
Halmos et al.
J. Clin. Endocrinol. Metab. 2000;85:2564-2571.
ABSTRACT | FULL TEXT  

The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Grover et al.
CMAJ 2000;162:977-983.
ABSTRACT | FULL TEXT  

Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen
Nam et al.
JCO 2000;18:1036-1036.
ABSTRACT | FULL TEXT  

Prostate Cancer Practice Patterns and Quality of Life: the Prostate Cancer Outcomes Study
Potosky et al.
JNCI J Natl Cancer Inst 1999;91:1719-1724.
FULL TEXT  

Antiangiogenic Activity of Prostate-Specific Antigen
Fortier et al.
JNCI J Natl Cancer Inst 1999;91:1635-1640.
ABSTRACT | FULL TEXT  

Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part I: Evidence of the Effects of Screening in Recent Prostate Cancer Incidence, Mortality, and Survival Rates
Hankey et al.
JNCI J Natl Cancer Inst 1999;91:1017-1024.
ABSTRACT | FULL TEXT  

Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer Mortality
Feuer et al.
JNCI J Natl Cancer Inst 1999;91:1025-1032.
ABSTRACT | FULL TEXT  

Geriatrics and the Limits of Modern Medicine
Goodwin
NEJM 1999;340:1283-1285.
FULL TEXT  

Inhibition of PC-3 Human Androgen-independent Prostate Cancer and Its Metastases by Cytotoxic Somatostatin Analogue AN-238
Plonowski et al.
Cancer Res. 1999;59:1947-1953.
ABSTRACT | FULL TEXT  

Treatment of hormone-refractory prostate cancer
Medina et al.
J Oncol Pharm Pract 1999;5:32-48.
ABSTRACT  

Epidemiological Studies and Effects of Environmental Estrogens
Waddell
International Journal of Toxicology 1998;17:173-191.
ABSTRACT  

Controversies in Prostate Cancer Screening: Analogies to the Early Lung Cancer Screening Debate
Collins and Barry
JAMA 1996;276:1976-1979.
ABSTRACT  

Predictive Properties of Serum Prostate-Specific Antigen Testing in a Community-Based Setting
Jacobsen et al.
Arch Intern Med 1996;156:2462-2468.
ABSTRACT  

Longitudinal Screening for Prostate Cancer With Prostate-Specific Antigen
Smith et al.
JAMA 1996;276:1309-1315.
ABSTRACT  

The Melanoma Epidemic: Is Increased Surveillance the Solution or the Problem?
Swerlick and Chen
Arch Dermatol 1996;132:881-884.
ABSTRACT  

Urology
Albertsen
JAMA 1996;275:1857-1858.
ABSTRACT  

Survival and Conservative Treatment for Localized Prostate Cancer-Reply
Albertsen
JAMA 1996;275:32-32.
ABSTRACT  

Screening for Prostate Cancer with Prostate-Specific Antigen -- An Examination of the Evidence
Woolf
NEJM 1995;333:1401-1405.
FULL TEXT  

Incidence of Prostate Cancer Diagnosis in the Eras Before and After Serum Prostate-Specific Antigen Testing
Jacobsen et al.
JAMA 1995;274:1445-1449.
ABSTRACT  

Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer
Albertsen et al.
JAMA 1995;274:626-631.
ABSTRACT